Remogliflozin etabonate – 1 mg

Brand:
Cayman
CAS:
442201-24-3
Storage:
-20
UN-No:
Non-Hazardous - /

Remogliflozin etabonate is a prodrug form of the sodium-glucose transporter 2 (SGLT2) inhibitor remogliflozin A (Item No. 14340).{41327} Remogliflozin etabonate inhibits human SGLT2 and SGLT1 (Kis = 1.95 and 43.1 μM, respectively). It inhibits increases in plasma glucose levels in a glucose tolerance test in a rat model of diabetes induced by streptozotocin (STZ; Item No. 13104) when administered at doses of 3 and 10 mg/ml. Remogliflozin etabonate (10 and 30 mg/kg twice per day for 6 weeks) also increases fasting plasma insulin levels and reduces fasting plasma glucose and triglyceride levels, as well as urinary glucose excretion, in a db/db mouse model of diabetes with hyperinsulinemia and obesity.  

 

SKU: - Category:

Description

A prodrug form of remogliflozin A; inhibits human SGLT2 and SGLT1 (Kis = 1.95 and 43.1 μM, respectively); inhibits increases in plasma glucose levels in a glucose tolerance test in a rat model of STZ-induced diabetes at 3 and 10 mg/ml; increases fasting plasma insulin levels and reduces fasting plasma glucose and triglyceride levels, as well as urinary glucose excretion, in a db/db mouse model of diabetes with hyperinsulinemia and obesity at 10 and 30 mg/kg twice per day for 6 weeks


Formal name: 5-methyl-4-[[4-(1-methylethoxy)phenyl]methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl, β-D-glucopyranoside 6-(ethyl carbonate)

Synonyms:  GSK189075

Molecular weight: 522.6

CAS: 442201-24-3

Purity: ≥98%

Formulation: A solid


Product Type|Biochemicals|Transporter & Exchanger Modulators||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Dyslipidemias||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Obesity